Access Keys:
Skip to content (Access Key - 0)

Center for Cancer Research National Cancer Institute
Office of Science and Technology Partnerships

Antibody Development

CCR has established partnerships with Rockland Immunochemicals and Epitomics for the development of polyclonal and monoclonal antibodies.

1) Rockland Immunochemicals

In 2005, CCR formed a partnership with Rockland Immunochemicals for the development of rabbit polyclonal antibodies against key phospho- and non-phospho-proteins implicated in cancer. The antibodies are produced by Rockland and validated by CCR investigators.

Over 80 polyclonal antibodies were delivered to CCR investigators at no cost to CCR or the investigators. In  2011 the Rockland/CCR MTA was amended to include the production of mouse monoclonal antibodies at no cost. 

For each successful polyclonal or monoclonal antibody produced by Rockland and validated by CCR Rockland will deliver to the validating investigators up to five milligrams of each polyclonal collaboration antibody, three milligrams of each monoclonal collaboration antibody and one vial of Rockland antibodies for validation purposes. 

To request an antibody please log into the ABCC/CCR/Rockland file sharing system and click on “Request New Antibody” complete the form and submit or contact David Chimento first to discuss your project. 

David Chimento, Ph.D
Antibody Validation Group Leader
Rockland Immunochemicals, Inc.
P.O. Box 326, Gilbertsville, PA 19525
610-367-7825 fax

2) Epitomics

In December 2008, the OSTP established a unique partnership with Epitomics Inc. for the development of rabbit monoclonal antibodies.

Rabbit monoclonal antibodies recognize many antigens that are not immunogenic in mice, including small molecules haptens, some cell surface epitopes, modified sites (e.g., phosphorylation, acetylation, methylation, glycosylation, etc.) and most rodent proteins. The antibodies are generally of higher affinity than those from mice. Results obtained from Epitomics and other researchers indicate that the binding affinity of rabbit monoclonal antibodies is on average 50 to 100 times higher, offering better sensitivity and specificity in biological assays. The rabbit system offers 40 times as many lymphocytes compared to mouse, the 240E cell line used for fusion is much more robust than any of the mouse cell lines used for fusion and because of the large size of the rabbit spleen, more fusion experiments can be performed.

The cost to the investigator for the development of one custom rabbit monoclonal antibody is $2900 (total cost $5800, 50% OSTP subsidy).  Investigators are responsible for validating the antibodies through the production process.

Please download the document Epitomics Custom Service Quote for detailed information on:

  • Phases of Development and Cost
  • Project Detail and Timeline
  • Additional Services (no subsidy)

To request an antibody investigators should contact Julia Prescott (Epitomics’ Project Manager), discuss their protein target for antibody development and if Epitomics agrees to develop the antibody they should send an email to Shoshana Segal with the name and species of the target protein. If the antigen is modified, they should specify the exact modification (e.g., phosphorylated, acetylated, methylated, glycosylated, etc.).  Investigators should also provide contact information for their AO and Purchasing Agent so that subsidy funds can be transferred to their CAN/Center Number.

A Soul Source Justification letter to be included in the purchase order will be sent to the investigator.  When placing the order investigators should charge the full cost of the project to their CAN/Center Number.  Subsidy funds will be transferred to the investigator’s CAN/Center Number after each phase of production (see attachment) unless the project is terminated.

Contact information for Julia:

Julia Prescott, Ph.D., Project Manager
Epitomics, Inc.
Phone: 650-583-6688 x281

Antibodies produced by Rockland and Epitomics are commercialized 60 to 90 days after completion of bulk production and delivery to the investigators.

For questions regarding the two partnerships please contact Shosh Segal by phone 301-496-0923 or E-mail

Added by Shilling, Jeffrey (NIH/NCI) [E] , last edited by Goldstein, David (NIH/NCI) [E] on Mar 20, 2012 16:18